University of New Mexico life sciences spin-out Tyrosine Pharma announces name change to Zocere.

Tyrosine Pharma, a spin-out of the University of New Mexico focused on developing stroke therapies, has announced a name change.

Now known as Zocere, the Albuquerque-based firm said the name change better reflected its development of drugs to combat stroke and other neurological conditions.

Zocere raised $250,000 in seed backing last year from angel investment coalition New Mexico Angels.

Wayne Laslie, president and chief exectuive, said: “We all know someone who has been struck down by stroke and how frustrating it is for physicians and family members to have so few treatment options. Zocere is working to change that by developing injectable, brain-protecting drugs that have the potential to reduce deaths, long-term disability and the financial impact of stroke.”